Carole Ben-Maimon, M.D. is the President and CEO of Larimar Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases. With a solid educational background, she earned her B.S. from the University of Pennsylvania and her M.D. from Jefferson...
Carole Ben-Maimon, M.D. is the President and CEO of Larimar Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases. With a solid educational background, she earned her B.S. from the University of Pennsylvania and her M.D. from Jefferson Medical College. Dr. Ben-Maimon has a rich experience in the pharmaceutical industry, holding leadership roles in several companies. Before joining Larimar in May 2020, she served as the CEO of Chondrial Therapeutics and was involved in strategic roles at companies like Impax Laboratories and Teva Pharmaceuticals. During her time at Larimar, she has played a crucial role in steering the company towards its goals, ensuring it remains at the forefront of biopharmaceutical innovation. In 2023, her total compensation was reported at $865,999, which reflects her performance-based bonus structure linked to corporate achievements. Besides her leadership position, Dr. Ben-Maimon's experience gives her a comprehensive view of the biopharmaceutical landscape, making her a significant figure in driving forward Larimar's mission to address unmet medical needs.